Browse > Article
http://dx.doi.org/10.5765/jkacap.2013.24.1.13

Neuroleptic Malignant Syndrome in Children and Adolescents : A Review  

Kwack, Young-Sook (Department of Psychiatry, Jeju National University School of Medicine)
Ryu, Jae-Sung (Department of Psychiatry, Jeju National University Hospital)
Publication Information
Journal of the Korean Academy of Child and Adolescent Psychiatry / v.24, no.1, 2013 , pp. 13-20 More about this Journal
Abstract
Neuroleptic malignant syndrome (NMS) is a severe iatrogenic complication of treatment with antipsychotic medication. The aim of this review is to provide the clinical characteristics and treatments of children and adolescents with NMS. Searches were conducted in Medline, Korean studies Information Service System (KISS), and Research Information Service System (RISS). Sixteen case reports and two review articles were selected in Medline, and two Korean cases reported in department of emergency medicine and pediatrics were selected from RISS. Heterogeneous and atypical presentations of NMS were observed in children and adolescents. Some noticeable differences were observed between adult patients and child patients with NMS. In addition, symptom presentations related to atypical antipsychotic agents differed from those of typical ones. In treatment, bromocriptine and benzodiazepine were recommended for management of symptoms. In particular, electroconvulsive therapy (ECT) was a useful treatment option. For prevention and early detection of NMS in children and adolescents, evaluation of risk factors and understanding of diagnostic features of NMS are very important.
Keywords
Neuroleptic Malignant Syndrome; Child; Adolescent;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004;26:1105- 1108.   DOI   ScienceOn
2 Abu-Kishk I, Toledano M, Reis A, Daniel D, Berkovitch M. Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic. J Toxicol Clin Toxicol 2004;42:921-925.   DOI   ScienceOn
3 Hillis RE, Lee DA. Viral encephalitis complicated by neuroleptic malignant syndrome in a 7-year-old girl. Pediatr Emerg Care 2003; 19:99-100.   DOI   ScienceOn
4 Hanft A, Eggleston CF, Bourgeois JA. Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 2004;14:481-487.   DOI   ScienceOn
5 Ghaziuddin N, Alkhouri I, Champine D, Quinlan P, Fluent T, Ghaziuddin M. ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment. J ECT 2002;18:95-98.   DOI   ScienceOn
6 Ghaziuddin N, Laughrin D, Giordani B. Cognitive side effects of electroconvulsive therapy in adolescents. J Child Adolesc Psychopharmacol 2000;10:269-276.   DOI   ScienceOn
7 Steingard R, Khan A, Gonzalez A, Herzog DB. Neuroleptic malignant syndrome: review of experience with children and adolescents. J Child Adolesc Psychopharmacol 1992;2:183-198.   DOI   ScienceOn
8 Bahn GH, Cho SC, Hong KE, Kim YS, Chung SJ. A case of Clozapine trial for a manic episode suffered by an adolescent recovering from neuroleptic malignant syndrome. Korean J Child & Adol Psychiatr 1998;9:247-252.   과학기술학회마을
9 Dahlstrom JE, Cookman J, Jain S. Joubert syndrome: an affected female with bilateral colobomata. Pathology 2000;32:283-285.   DOI
10 Vurucu S, Congologlu A, Altun D, Unay B, Akin R. Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome. J Natl Med Assoc 2009;101:273-275.   DOI
11 Bellamy CJ, Kane-Gill SL, Falcione BA, Seybert AL. Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. J Trauma 2009;66:954-958.   DOI   ScienceOn
12 Martinez HR, Cantu-Martínez L, González HC, Flores Lde L, Villarreal HJ, Onofre-Castillo J. Epilepsy, parkinsonism, and neuroleptic malignant syndrome in a child. J Child Neurol 2006;21: 1073-1075.   DOI
13 Rodnitzky RL. Drug-induced movement disorders in children and adolescents. Expert Opin Drug Saf 2005;4:191-102.
14 Pranzatelli MR, Mott SH, Pavlakis SG, Conry JA, Tate ED. Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder. Pediatr Neurol 1994;10:131-140.   DOI   ScienceOn
15 Lima B, Neves G, Nora M. Juvenile Parkinsonism: clinical and metabolic characteristics. J Neurol Neurosurg Psychiatry 1987;50:345-348.   DOI
16 Yokochi M, Narabayashi H, Iizuka R, Nagatsu T. Juvenile parkinsonism--some clinical, pharmacological, and neuropathological aspects. Adv Neurol 1984;40:407-413.
17 Park-Matsumoto YC, Tazawa T. [Valproate induced parkinsonism]. No To Shinkei 1998;50:81-84.
18 Ring HA, Trimble MR, Costa DC, Moriarty J, Verhoeff NP, Ell PJ. Striatal dopamine receptor binding in epileptic psychoses. Biol Psychiatry 1994;35:375-380.   DOI   ScienceOn
19 Starr MS. The role of dopamine in epilepsy. Synapse 1996;22:159-194.   DOI
20 Hillis RE, Lee DA. Viral encephalitis complicated by neuroleptic malignant syndrome in a 7-year-old girl. Pediatr Emerg Care 2003; 19:99-100.   DOI   ScienceOn
21 Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 2007;30:47-51.   DOI   ScienceOn
22 Erermis S, Bildik T, Tamar M, Gockay A, Karasoy H, Ercan ES. Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl. Clin Toxicol (Phila) 2007;45:277-280.   DOI   ScienceOn
23 Muhammed K, Raman P. Simultaneous occurrence of toxic epidermal necrolysis and neuroleptic malignant syndrome. Indian J Dermatol Venereol Leprol 2005;71:270-272.   DOI
24 Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003;2:21-35.   DOI   ScienceOn
25 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington DC: American Psychiatric Association;2000.
26 Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol 2009;19:415-422.   DOI   ScienceOn
27 Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22: 1004-1020.   DOI   ScienceOn
28 Ty EB, Rothner AD. Neuroleptic malignant syndrome in children and adolescents. J Child Neurol 2001;16:157-163.
29 Ghaziuddin N, Kutcher SP, Knapp P, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry 2004;43: 1521-1539.   DOI   ScienceOn
30 Shoirah H, Hamoda HM. Electroconvulsive therapy in children and adolescents. Expert Rev Neurother 2011;11:127-137.   DOI   ScienceOn
31 Rey JM, Walter G. Half a century of ECT use in young people. Am J Psychiatry 1997;154:595-602.   DOI   ScienceOn
32 Aubas S, Biboulet P, Daures JP, du Cailar J. [Incidence and etiology of cardiac arrest occurring during the peroperative period and in the recovery room. Apropos of 102,468 anesthesia cases]. Ann Fr Anesth Reanim 1991;10:436-442.   DOI   ScienceOn
33 Mansheim P. ECT in the treatment of a depressed adolescent with meningomyelocele, hydrocephalus, and seizures. J Clin Psychiatry 1983;44:385-386.
34 Kutcher S, Robertson HA. Electroconvulsive therapy in treatment resistant bipolar youth. J Child Adolesc Psychopharmacol 1995;5: 167-175.   DOI
35 Ghaziuddin N, DeQuardo JR, Ghaziuddin M, King CA. Electroconvulsive treatment of a bipolar adolescent postcraniotomy for brain stem astrocytoma. J Child Adolesc Psychopharmacol 1999;9:63-69.   DOI
36 Viparelli U, Viparelli G. ECT and Grand Mal Epilepsy. Convuls Ther 1992;8:39-42.
37 Griesemer DA, Kellner CH, Beale MD, Smith GM. Electroconvulsive therapy for treatment of intractable seizures. Initial findings in two children. Neurology 1997;49:1389-1392.   DOI   ScienceOn
38 Hill MA, Courvoisie H, Dawkins K, Nofal P, Thomas B. ECT for the treatment of intractable mania in two prepubertal male children. Convuls Ther 1997;13:74-82.
39 Ghaziuddin N, King CA, Naylor MW, Ghaziuddin M, Chaudhary N, Giordani B, et al. Electroconvulsive treatment in adolescents with pharmacotherapy-refractory depression. J Child Adolesc Psychopharmacol 1996;6:259-271.   DOI
40 Bailine SH, Petrides G, Doft M, Lui G. Indications for the use of propofol in electroconvulsive therapy. J ECT 2003;19:129-132.   DOI   ScienceOn
41 Schneekloth TD, Rummans TA, Logan KM. Electroconvulsive Therapy in Adolescents. Convuls Ther 1993;9:158-166.
42 Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38:187-194.   DOI   ScienceOn
43 Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008;69:1157-1165.   DOI
44 Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-470.   DOI
45 Khan HM, Syed NA, Sheerani M, Khcalani B, Kamal A, Wasay M. Neuroleptic malignant syndrome: need for early diagnosis and therapy. J Ayub Med Coll Abbottabad 2006;18:17-21.
46 Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin 1997;13:763-783.   DOI
47 Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155: 1113-1116.   DOI   ScienceOn
48 Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991;148:880-882.   DOI   ScienceOn
49 Chungh DS, Kim BN, Cho SC. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol 2005;19:422-425.   DOI
50 Park KH, Jung SK, Yim HE, Yoo KH, Hong YS, Lee JW. A case of acute renal failure due to rhabdomyolysis associated with neuroleptic malignant syndrome. J Korean Soc Pediatr Nephrol 2009;13(2):1226-5292.   과학기술학회마을   DOI   ScienceOn
51 Choi HJ, Oh SB. Neuroleptic malignant syndrome complicated with acute renal failure secondary to quetiapine: a case report. J Korean Soc Emerg Med 2010;21:278-281.
52 Viejo LF, Morales V, Punal P, Perez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand 2003;107:45-49.   DOI   ScienceOn
53 Henderson T. Neuroleptic malignant syndrome in adolescents: four probable cases in the Western Cape. S Afr Med J 2011;101:405-407.
54 Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K. Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Mol Psychiatry 2004;9:293-298.   DOI   ScienceOn
55 Akpaffiong MJ, Ruiz P. Neuroleptic malignant syndrome: a complication of neuroleptics and cocaine abuse. Psychiatr Q 1991;62:299- 309.   DOI
56 Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004;22: 389-411.   DOI   ScienceOn
57 Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet 2003;117B:57-60.   DOI   ScienceOn
58 Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-1145.   DOI   ScienceOn